FDA halts pediatric trials of Amgen drug

The U.S. Food and Drug Administration said Tuesday that it had directed Amgen Inc. to stop pediatric studies of one of its drugs after 14-year-old patient died. The FDA said it doesn’t know yet whether Sensipar – which treats a condition that can cause brittle bones, abdominal pain and kidney stones – was a factor in the teen’s death, but wanted the clinical trials stopped until that could be determined.

Read more about the Amgen pediatric trials…


0 Responses to “FDA halts pediatric trials of Amgen drug”

  1. Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 435 other followers

Contact Us:

Hissey Kientz, LLP

9442 Capital of Texas Hwy N.

Arboretum Plaza One, Suite 400

Austin, Texas 78759

Toll-free: (866) 275-4454

Facsimile: (512) 320-9101

Email: info@hkllp.com

Sponsored By:

Hissey Kientz, LLP (Austin, TX)

Attorney Michael Hissey is responsible for the content of this website.

%d bloggers like this: